{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:25:03Z","timestamp":1790997903657,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014720","name":"Beirut Arab University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014720","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015732","name":"Bah\u00e7e\u015fehir University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015732","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.bioorg.2025.108850","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T15:49:44Z","timestamp":1754495384000},"page":"108850","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Investigation of novel nimesulide derivatives against breast cancer"],"prefix":"10.1016","volume":"164","author":[{"given":"Kaan","family":"Birg\u00fcl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130rem","family":"Atl\u0131han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damla","family":"Dere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kemal","family":"Yelek\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinar Mega","family":"Tiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oya","family":"Orun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015e. G\u00fcniz","family":"K\u00fc\u00e7\u00fckg\u00fczel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.108850_bb0005","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.3390\/cancers13174287","article-title":"Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review","volume":"13","author":"\u0141ukasiewicz","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2025.108850_bb0010","first-page":"412","article-title":"Biological subtypes of breast cancer: prognostic and therapeutic implications, world","volume":"5","author":"Yersal","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.108850_bb0015","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3390\/jcm12041375","article-title":"Understanding breast Cancer aggressiveness and its implications in diagnosis and treatment","volume":"12","author":"Afifi","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bioorg.2025.108850_bb0020","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3390\/cancers15041320","article-title":"Targeted therapy and mechanisms of drug resistance in breast Cancer","volume":"15","author":"Kinnel","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2025.108850_bb0025","first-page":"5125","article-title":"Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines","volume":"56","author":"Liu","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108850_bb0030","first-page":"677","article-title":"Cyclooxygenase-2 and the inflammogenesis of breast cancer, world","volume":"5","author":"Harris","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.108850_bb0035","first-page":"4359","article-title":"Impact of Cyclooxygenase-2 in breast Cancer","volume":"31","author":"Hoellen","year":"2011","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bioorg.2025.108850_bb0040","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10787-009-8049-8","article-title":"Cyclooxygenase-2 (COX-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung","volume":"17","author":"Harris","year":"2009","journal-title":"Inflammopharmacology"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108850_bb0045","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108850_bb0050","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12865-020-00347-y","article-title":"Prostaglandin E2 stimulates COX-2 expression via mitogen-activated protein kinase p38 but not ERK in human follicular dendritic cell-like cells","volume":"21","author":"Cho","year":"2020","journal-title":"BMC Immunol."},{"key":"10.1016\/j.bioorg.2025.108850_bb0055","article-title":"Nimesulide \u2013 Actions and Uses, Birkh\u00e4user Verlag","author":"Rainsford","year":"2005","journal-title":"Basel"},{"key":"10.1016\/j.bioorg.2025.108850_bb0060","first-page":"943","article-title":"Effects of cyclooxygenase 2 inhibitors on biological traits of nasopharyngeal carcinoma cells","volume":"25","author":"Chen","year":"2004","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bioorg.2025.108850_bb0065","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s000110050221","article-title":"In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview","volume":"46","author":"Famaey","year":"1997","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.bioorg.2025.108850_bb0070","doi-asserted-by":"crossref","first-page":"8021","DOI":"10.1038\/sj.onc.1206837","article-title":"Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition","volume":"22","author":"Totzke","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2025.108850_bb0075","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1016\/j.ejmech.2009.02.030","article-title":"Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide","volume":"44","author":"Karaku\u015f","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108850_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.102966","article-title":"Nimesulide analogues: from anti-inflammatory to antitumor agents","volume":"88","author":"Catarro","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108850_bb0085","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3233\/BD-201063","article-title":"Mini review: the FDA-approved prescription drugs that target the MAPK signaling pathway in women with breast Cancer","volume":"40","author":"Khojasteh Poor","year":"2021","journal-title":"Breast Dis."},{"key":"10.1016\/j.bioorg.2025.108850_bb0090","first-page":"291","article-title":"Synthesis, spectroscopy characterization and biological activities of some novel 1-(3-(N,N-dimethylamino)-1-(5-substituted thiophene-2-yl))propylidene semicarbazone Mannich base derivatives","volume":"7","author":"Gopi","year":"2018","journal-title":"Beni-Suef Univ. J. Basic Appl. Sci."},{"key":"10.1016\/j.bioorg.2025.108850_bb0095","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S2221-1691(12)60358-X","article-title":"Synthesis, molecular docking and biological evaluation of 4-cycloalkylideneamino-1,2-naphthoquinone semicarbazones as anticancer agents","volume":"2","author":"Shukla","year":"2012","journal-title":"Asian Pac. J. Trop. Biomed."},{"key":"10.1016\/j.bioorg.2025.108850_bb0100","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ejmech.2014.10.022","article-title":"Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine derivatives possessing diaryl semicarbazone scaffolds as potent antitumor agents","volume":"87","author":"Liu","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108850_bb0105","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3797\/scipharm.aut-00-34","article-title":"Synthesis and antitumour activity of some aryl semicarbazones","volume":"68","author":"Pandeya","year":"2000","journal-title":"Sci. Pharm."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108850_bb0110","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1248\/cpb.c18-00738","article-title":"Semicarbazone derivatives bearing phenyl moiety: synthesis, anticancer activity, cell cycle, apoptosis-inducing and metabolic stability study","volume":"67","author":"Ma","year":"2019","journal-title":"Chem. Pharm. Bull."},{"issue":"6","key":"10.1016\/j.bioorg.2025.108850_bb0115","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S2221-1691(12)60072-0","article-title":"In vivo anticancer activity of vanillin semicarbazone","volume":"2","author":"Ali","year":"2012","journal-title":"Asian Pac. J. Trop. Biomed."},{"key":"10.1016\/j.bioorg.2025.108850_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105968","article-title":"The effect of novel synthetic semicarbazone- and thiosemicarbazone-linked 1,2,3-triazoles on the apoptotic markers, VEGFR-2, and cell cycle of myeloid leukemia","volume":"127","author":"Othman","year":"2022","journal-title":"Bioorg. Chem."},{"issue":"13","key":"10.1016\/j.bioorg.2025.108850_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115557","article-title":"Synthesis, cytotoxicity, and in vivo antitumor activity study of parthenolide semicarbazones and thiosemicarbazones","volume":"28","author":"Jia","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108850_bb0130","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF03226418","article-title":"Detection of nimesulide metabolites in rat plasma and hepatic subcellular fractions by HPLC-UV\/DAD and LC-MS\/MS studies","volume":"30","author":"K\u00fc\u00e7\u00fckg\u00fczel","year":"2005","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108850_bb0135","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3390\/cancers11040513","article-title":"Divergent dynamics and functions of ERK MAP kinase signaling in development, homeostasis and cancer: lessons from fluorescent bioimaging","volume":"11","author":"Muta","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2025.108850_bb0140","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/bs.acr.2018.02.004","article-title":"Extracellular-regulated kinases: signaling from ras to ERK substrates to control biological outcomes","volume":"138","author":"Eblen","year":"2018","journal-title":"Adv. Cancer Res."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108850_bb0145","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1\/2 MAP kinases: structure, function, and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharmacol. Res."},{"issue":"22","key":"10.1016\/j.bioorg.2025.108850_bb0150","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1002\/cncr.28864","article-title":"The MAPK pathway across different malignancies: a new perspective","volume":"120","author":"Burotto","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2025.108850_bb0155","first-page":"370","article-title":"Nimesulide inhibits proliferation and induces apoptosis of pancreatic cancer cells by enhancing expression of PTEN","volume":"16","author":"Chu","year":"2008","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.bioorg.2025.108850_bb0160","article-title":"Anti-proliferative effects of Piroxicam and Nimesulide on A431 human squamous carcinoma cell line","volume":"10","author":"Khodaie","year":"2017","journal-title":"In International Journal of Cancer Management"},{"key":"10.1016\/j.bioorg.2025.108850_bb0165","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3748\/wjg.v9.i5.915","article-title":"Nimesulide inhibits proliferationviainduction of apoptosis and cell cycle arrest in human gastric adenocarcinoma cell line","volume":"9","author":"Li","year":"2003","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bioorg.2025.108850_bb0170","article-title":"Nimesulide derivatives reduced cell proliferation against breast and ovarian cancer: synthesis, characterization, biological assessment, and crystal structure","author":"Jaragh-Alhadad","year":"2025","journal-title":"Kuwait J. Sci. Elsevier BV"},{"key":"10.1016\/j.bioorg.2025.108850_bb0175","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3390\/pharmaceutics15071796","article-title":"Triple negative breast Cancer treatment options and limitations: future outlook","volume":"15","author":"Obidiro","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2025.108850_bb0180","series-title":"Molecular Cell Biology","author":"Lodish","year":"2005"},{"key":"10.1016\/j.bioorg.2025.108850_bb0185","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-020-00949-4","article-title":"The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy","volume":"17;13(1)","author":"Yuan","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"19","key":"10.1016\/j.bioorg.2025.108850_bb0190","doi-asserted-by":"crossref","first-page":"10260","DOI":"10.3390\/ijms221910260","article-title":"Growth factors, PI3K\/AKT\/mTOR and MAPK signaling pathways in colorectal Cancer pathogenesis: where are we now?","volume":"22","author":"Stefani","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108850_bb0195","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1186\/s12967-024-05998-8","article-title":"The role of MAPK pathway in gastric cancer: unveiling molecular crosstalk and therapeutic prospects","volume":"22","author":"Yuan","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bioorg.2025.108850_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119499","article-title":"Interplay between MAPK\/ERK signaling pathway and MicroRNAs: a crucial mechanism regulating cancer cell metabolism and tumor progression","volume":"278","author":"Asl","year":"2021","journal-title":"Life Sci."},{"issue":"10","key":"10.1016\/j.bioorg.2025.108850_bb0205","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3390\/biom13101555","article-title":"Navigating the ERK1\/2 MAPK Cascade","volume":"13","author":"Martin-Vega","year":"2023","journal-title":"Biomolecules"},{"issue":"9","key":"10.1016\/j.bioorg.2025.108850_bb0210","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.trecan.2020.05.009","article-title":"Clinical development of BRAF plus MEK inhibitor combinations","volume":"6","author":"Subbiah","year":"2020","journal-title":"Trends Cancer."},{"issue":"21","key":"10.1016\/j.bioorg.2025.108850_bb0215","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1158\/1078-0432.CCR-21-2138","article-title":"Molecular pathways and mechanisms of BRAF in Cancer therapy","volume":"28","author":"Poulikakos","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108850_bb0220","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2021.05.010","article-title":"RAF-MEK-ERK pathway in cancer evolution and treatment","volume":"85","author":"Ullah","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"26","key":"10.1016\/j.bioorg.2025.108850_bb0225","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"BRIM-3 study group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108850_bb0230","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"METRIC study group. Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.bioorg.2025.108850_bb0235","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108850_bb0240","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.bioorg.2025.108850_bb0245","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1158\/1535-7163.MCT-17-0456","article-title":"Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1\/2 Inhibitor BVD-523 (Ulixertinib)","volume":"16","author":"Germann","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2025.108850_bb0250","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2174\/1570178616666190401193928","article-title":"Synthesis and biological potentials of 5-aryl-N-[4-(trifluoromethyl) phenyl]-1,3,4-oxadiazol-2-amines","volume":"17","author":"Ahsan","year":"2020","journal-title":"Lett. Org. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2025.108850_bb0255","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202300766","article-title":"Synthesis and Evaluation of Novel Metacetamol Derivatives with Hydrazone Moiety as Anticancer and Antimicrobial Agents","volume":"20","author":"\u015eenkarde\u015f","year":"2023","journal-title":"Chem. Biodivers."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108850_bb0260","doi-asserted-by":"crossref","first-page":"265","DOI":"10.26650\/IstanbulJPharm.2022.1094112","article-title":"Effect of flurbiprofen derivative (SGK597) on cell proliferation and apoptosis of breast cancer cell lines","volume":"52","author":"Atl\u0131han","year":"2022","journal-title":"Istanbul J. Pharm."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108850_bb0265","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2025.108850_bb0270","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.heliyon.2024.e35020","article-title":"Repurposing of known drugs from multiple libraries to identify novel and potential selective inhibitors of HDAC6 via in silico approach and molecular modeling","volume":"10","author":"Mert","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.bioorg.2025.108850_bb0275","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/jcc.20289","article-title":"Scalable molecular dynamics with NAMD","volume":"26","author":"Phillips","year":"2005","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2025.108850_bb0280","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1021\/acs.jctc.5b00935","article-title":"CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM\/OpenMM simulations using the CHARMM36 additive force field","volume":"12","author":"Lee","year":"2016","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.bioorg.2025.108850_bb0285","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825007308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825007308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T02:28:30Z","timestamp":1762223310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825007308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":57,"alternative-id":["S0045206825007308"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108850","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigation of novel nimesulide derivatives against breast cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108850","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108850"}}